View in EDS

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.

Saved in:
Bibliographic Details
Title: Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Authors: Silk JD; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com., Abbott RJM; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Adams KJ; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Bennett AD; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Brett S; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Cornforth TV; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Crossland KL; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Figueroa DJ; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Jing J; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., O'Connor C; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Pachnio A; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Patasic L; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Peredo CE; Cell and Gene Therapy Product Development and Supply, Analytical Development, GlaxoSmithKline, Collegeville, PA., Quattrini A; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Quinn LL; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Rust AG; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Saini M; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Sanderson JP; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Steiner D; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Tavano B; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Viswanathan P; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Wiedermann GE; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Wong R; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Jakobsen BK; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Britten CM; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Gerry AB; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Brewer JE; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com.
Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2022 Jan 01; Vol. 208 (1), pp. 169-180. Date of Electronic Publication: 2021 Dec 01.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 2985117R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34853077
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Silk+JD%22">Silk JD</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com.<br /><searchLink fieldCode="AU" term="%22Abbott+RJM%22">Abbott RJM</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Adams+KJ%22">Adams KJ</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Bennett+AD%22">Bennett AD</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Brett+S%22">Brett S</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Cornforth+TV%22">Cornforth TV</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Crossland+KL%22">Crossland KL</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Figueroa+DJ%22">Figueroa DJ</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Jing+J%22">Jing J</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22O'Connor+C%22">O'Connor C</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pachnio+A%22">Pachnio A</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Patasic+L%22">Patasic L</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Peredo+CE%22">Peredo CE</searchLink>; Cell and Gene Therapy Product Development and Supply, Analytical Development, GlaxoSmithKline, Collegeville, PA.<br /><searchLink fieldCode="AU" term="%22Quattrini+A%22">Quattrini A</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Quinn+LL%22">Quinn LL</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Rust+AG%22">Rust AG</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Saini+M%22">Saini M</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Sanderson+JP%22">Sanderson JP</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Steiner+D%22">Steiner D</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Tavano+B%22">Tavano B</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Viswanathan+P%22">Viswanathan P</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wiedermann+GE%22">Wiedermann GE</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wong+R%22">Wong R</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Jakobsen+BK%22">Jakobsen BK</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Britten+CM%22">Britten CM</searchLink>; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Gerry+AB%22">Gerry AB</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Brewer+JE%22">Brewer JE</searchLink>; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985117R%22">Journal of immunology (Baltimore, Md. : 1950)</searchLink> [J Immunol] 2022 Jan 01; Vol. 208 (1), pp. 169-180. <i>Date of Electronic Publication: </i>2021 Dec 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985117R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1550-6606 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200221767%22">00221767 </searchLink><i>NLM ISO Abbreviation: </i>J Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34853077
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.4049/jimmunol.2001357
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 169
    Titles:
      – TitleFull: Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Silk JD
      – PersonEntity:
          Name:
            NameFull: Abbott RJM
      – PersonEntity:
          Name:
            NameFull: Adams KJ
      – PersonEntity:
          Name:
            NameFull: Bennett AD
      – PersonEntity:
          Name:
            NameFull: Brett S
      – PersonEntity:
          Name:
            NameFull: Cornforth TV
      – PersonEntity:
          Name:
            NameFull: Crossland KL
      – PersonEntity:
          Name:
            NameFull: Figueroa DJ
      – PersonEntity:
          Name:
            NameFull: Jing J
      – PersonEntity:
          Name:
            NameFull: O'Connor C
      – PersonEntity:
          Name:
            NameFull: Pachnio A
      – PersonEntity:
          Name:
            NameFull: Patasic L
      – PersonEntity:
          Name:
            NameFull: Peredo CE
      – PersonEntity:
          Name:
            NameFull: Quattrini A
      – PersonEntity:
          Name:
            NameFull: Quinn LL
      – PersonEntity:
          Name:
            NameFull: Rust AG
      – PersonEntity:
          Name:
            NameFull: Saini M
      – PersonEntity:
          Name:
            NameFull: Sanderson JP
      – PersonEntity:
          Name:
            NameFull: Steiner D
      – PersonEntity:
          Name:
            NameFull: Tavano B
      – PersonEntity:
          Name:
            NameFull: Viswanathan P
      – PersonEntity:
          Name:
            NameFull: Wiedermann GE
      – PersonEntity:
          Name:
            NameFull: Wong R
      – PersonEntity:
          Name:
            NameFull: Jakobsen BK
      – PersonEntity:
          Name:
            NameFull: Britten CM
      – PersonEntity:
          Name:
            NameFull: Gerry AB
      – PersonEntity:
          Name:
            NameFull: Brewer JE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2022 Jan 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1550-6606
          Numbering:
            – Type: volume
              Value: 208
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of immunology (Baltimore, Md. : 1950)
              Type: main
ResultId 1